FDA approved Parkinson's Therapeutic Found Effective in Treatment of Cancer

Technology #d-1152

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Vandivel Ganapathy, Ph.D.
Professor and Chairman, Cell Biology and Biochemistry. Dr. Ganapathy's research interests include cancer biology, development of novel anticancer drugs, interaction between gut microbiome and the host, and structure and function of the retina in health and disease.
External Link (www.ttuhsc.edu)
Yangzom Bhutia, Ph.D.
Research Assistant Professor, Cell Biology and Biochemistry
External Link (www.ttuhsc.edu)
Babu Ellappan
Research Instructor, Cell Biology and Biochemistry
Sabarish Ramachandran
Research Instructor, Cell Biology and Biochemistry
Managed By
David Snow
Director Intellectual Property 806-834-4989
Patent Protection

Provisional Patent Application Filed

Description:

Carbidopa is an FDA approved drug currently used in combination with Levo-Dopa to treat Parkinson’s disease.  Carbidopa, itself, has no effect on Parkinson's patients, but by increasing the availability of Levo-dopa in the brain enhances the effectiveness of the drug in patients.  As such, these two drugs are always prescribed together.

Researchers have found that Carbidopa, taken alone, is an effective anticancer drug for the treatment of pancreatic and breast cancer in mouse models.  The mechanism of action for Carbidopa is related to the inhibition of a critical immunosuppressive enzyme induced in tumor cells and inhibition of the generation of stress hormones that promote caner growth and progression. This discovery may imply broader applications in many types of cancer taken alone or in combination with other anticancer drugs. 

Reference Number: D-1152 

Market Applications:

  • Pharmaceuticals 
  • Health Care (Broad-scope Cancer Treatment)

Features, Benefits & Advantages:

  • Novel Cancer Therapy
  • Already FDA-approved
  • Is orally bioavailable
  • Potentially treats a broad range of cancers

Intellectual Property:

  • A U.S. Provisional Patent application (Serial 62/159,687) was filed on 5/12/15 for this invention. 

Development Stage:

  • The invention has been reduced to practice in pre-clinical trials. Clinical studies in cancer patients are currently being planned. 

Researchers:

  • Vandivel Ganapathy, Ph. D., Professor and Chairman, Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Yangzom Bhutia, Ph.D., Research Assistant Professor, Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Babu Ellappan, Research Instructor, Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Sabarish Ramachandran, Research Instructor, Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas. 

Keywords: carbidopa, glutamine, anti-tumor immunity and immunotherapy